Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan

Yoshimura, Akihiro; Kato, Taigo; Nakai, Yasutomo; Tsujihata, Masao; Toyoda, Shingo; Sato, Mototaka; Matsuzaki, Kyosuke; Nakata, Wataru; Takao, Tetsuya; Inoguchi, Syunsuke; Okuda, Yohei; Yamamichi, Gaku; Ishizuya, Yu; Yamamoto, Yoshiyuki; Hatano, Koji; Kawashima, Atsunari; Takada, Shingo; Inoue, Hitoshi; Nishimura, Kensaku; Miyake, Osamu; Fujita, Kazutoshi; Nakayama, Masashi; Nishimura, Kazuo; Nonomura, Norio

doi:https://doi.org/10.1007/s10147-024-02612-1

Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan

Yoshimura, Akihiro; Kato, Taigo; Nakai, Yasutomo et al.

International Journal of Clinical Oncology, 2024, 29(12), 1916-1924

アクセス数:3,410件（2025-07-13 01:16 集計）

固定URL: https://hdl.handle.net/11094/98275

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
IntJClinOncol_s10147-024-02612-1	pdf	なし	762 KB	100	2024.10.15

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan
著者	NRID 1000070981992 1000070981992 著者名 Yoshimura, Akihiro
	NRID 1000070648021 1000070648021 researchmap permalink taigokato taigokato Scopus Author ID 55414697500 55414697500 著者名 Kato, Taigo
	著者名 Nakai, Yasutomo
	著者名 Tsujihata, Masao
	著者名 Toyoda, Shingo
	著者名 Sato, Mototaka
	NRID 1000090747081 1000090747081 著者名 Matsuzaki, Kyosuke
	著者名 Nakata, Wataru
	NRID 1000030379177 1000030379177 著者名 Takao, Tetsuya
	著者名 Inoguchi, Syunsuke
	NRID 1000010964372 1000010964372 ORCID 0000-0001-9909-4200 0000-0001-9909-4200 researchmap permalink okudayohei okudayohei 著者名 Okuda, Yohei
	NRID 1000040882262 1000040882262 researchmap permalink urology-osaka-japan urology-osaka-japan 著者名 Yamamichi, Gaku
	NRID 1000000783854 1000000783854 researchmap permalink okiishi okiishi 著者名 Ishizuya, Yu
	NRID 1000090759557 1000090759557 researchmap permalink yoshi229 yoshi229 著者名 Yamamoto, Yoshiyuki
	NRID 1000060762234 1000060762234 researchmap permalink koji_hatano koji_hatano Scopus Author ID 14627167600 14627167600 著者名 Hatano, Koji
	NRID 1000050746568 1000050746568 researchmap permalink akawashima akawashima Scopus Author ID 9846139400 9846139400 著者名 Kawashima, Atsunari
	NRID 1000000379249 1000000379249 著者名 Takada, Shingo
	著者名 Inoue, Hitoshi
	著者名 Nishimura, Kensaku
	著者名 Miyake, Osamu
	NRID 1000050636181 1000050636181 著者名 Fujita, Kazutoshi
	NRID 1000040379178 1000040379178 著者名 Nakayama, Masashi
	NRID 1000080303957 1000080303957 著者名 Nishimura, Kazuo
	NRID 1000030263263 1000030263263 researchmap permalink read0185096 read0185096 Scopus Author ID 7005880662 7005880662 著者名 Nonomura, Norio
キーワード等	Immune checkpoint inhibitor
	Immune-related adverse event
	Non-clear cell renal cell carcinoma
	Renal cell carcinoma
内容	The version of record of this article, first published in International Journal of Clinical Oncology, is available online at Publisher’s website: https://doi.org/10.1007/s10147-024-02612-1.
抄録	Background: In metastatic clear cell renal cell carcinoma (ccRCC), recent studies have shown promising efficacy of immune checkpoint inhibitor (ICI) combination therapy. However, there are insufficient evidences about clinical efficacy and safety of ICI combination therapy in metastatic non-ccRCC (nccRCC). Methods: We retrospectively investigated 44 patients treated with nivolumab plus ipilimumab (ICI + ICI group) or anti-PD-1/PD-L1 inhibitor plus tyrosine kinase inhibitors (TKI) (ICI + TKI group), and assessed clinical efficacy in both groups. Results: Of all patients, overall response rate and disease control rate for ICI combination treatments were 36.3% and 75%, respectively. The median progression-free survival (PFS) and overall survival (OS) was 8.8 and 23.9 months, respectively. Multivariate analysis revealed that the presence of liver metastasis significantly affected worse PFS and OS (p = 0.035 and p = 0.049). Importantly, PFS and OS seemed similar in ICI + ICI group and ICI + TKI group (p = 0.778 and p = 0.559). Although the discontinuation rate of the combination therapy due to adverse effects in patients aged ≥ 75 years was significantly higher compared to that in patients aged < 75 years (45% versus 12%, p = 0.017), there were no significant differences in PFS and OS between two groups (p = 0.290 and p = 0.257, respectively). Conclusion: This study confirms clinical benefit of ICI combination therapy for metastatic nccRCC patients in real-world settings. Furthermore, the effectiveness of combination therapy was comparable between patients aged < 75 and those ≥75 years with respect to clinical prognosis.
出版者	Springer
収録物名	International Journal of Clinical Oncology
巻(号)	29(12)
ページ	1916-1924
刊行年月	2024-09-02
言語	英語
ハンドルURL	https://hdl.handle.net/11094/98275
PISSN	13419625
eISSN	14377772
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1007/s10147-024-02612-1
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCTERMS.bibliographicCitation	International Journal of Clinical Oncology. 2024, 29(12), p. 1916-1924
DC.title	Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan
DC.creator	Yoshimura, Akihiro
	Kato, Taigo
	Nakai, Yasutomo
	Tsujihata, Masao
	Toyoda, Shingo
	Sato, Mototaka
	Matsuzaki, Kyosuke
	Nakata, Wataru
	Takao, Tetsuya
	Inoguchi, Syunsuke
	Okuda, Yohei
	Yamamichi, Gaku
	Ishizuya, Yu
	Yamamoto, Yoshiyuki
	Hatano, Koji
	Kawashima, Atsunari
	Takada, Shingo
	Inoue, Hitoshi
	Nishimura, Kensaku
	Miyake, Osamu
	Fujita, Kazutoshi
	Nakayama, Masashi
	Nishimura, Kazuo
	Nonomura, Norio
DC.publisher	Springer
DC.language' scheme='DCTERMS.RFC1766	英語
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-09-02
DC.identifier	https://doi.org/10.1007/s10147-024-02612-1
DC.subject	Immune checkpoint inhibitor
	Immune-related adverse event
	Non-clear cell renal cell carcinoma
	Renal cell carcinoma
DC.description	The version of record of this article, first published in International Journal of Clinical Oncology, is available online at Publisher’s website: https://doi.org/10.1007/s10147-024-02612-1.
DCTERMS.abstract	Background: In metastatic clear cell renal cell carcinoma (ccRCC), recent studies have shown promising efficacy of immune checkpoint inhibitor (ICI) combination therapy. However, there are insufficient evidences about clinical efficacy and safety of ICI combination therapy in metastatic non-ccRCC (nccRCC). Methods: We retrospectively investigated 44 patients treated with nivolumab plus ipilimumab (ICI + ICI group) or anti-PD-1/PD-L1 inhibitor plus tyrosine kinase inhibitors (TKI) (ICI + TKI group), and assessed clinical efficacy in both groups. Results: Of all patients, overall response rate and disease control rate for ICI combination treatments were 36.3% and 75%, respectively. The median progression-free survival (PFS) and overall survival (OS) was 8.8 and 23.9 months, respectively. Multivariate analysis revealed that the presence of liver metastasis significantly affected worse PFS and OS (p = 0.035 and p = 0.049). Importantly, PFS and OS seemed similar in ICI + ICI group and ICI + TKI group (p = 0.778 and p = 0.559). Although the discontinuation rate of the combination therapy due to adverse effects in patients aged ≥ 75 years was significantly higher compared to that in patients aged < 75 years (45% versus 12%, p = 0.017), there were no significant differences in PFS and OS between two groups (p = 0.290 and p = 0.257, respectively). Conclusion: This study confirms clinical benefit of ICI combination therapy for metastatic nccRCC patients in real-world settings. Furthermore, the effectiveness of combination therapy was comparable between patients aged < 75 and those ≥75 years with respect to clinical prognosis.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	98275
citation_title	Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan
citation_author	Yoshimura, Akihiro
	Kato, Taigo
	Nakai, Yasutomo
	Tsujihata, Masao
	Toyoda, Shingo
	Sato, Mototaka
	Matsuzaki, Kyosuke
	Nakata, Wataru
	Takao, Tetsuya
	Inoguchi, Syunsuke
	Okuda, Yohei
	Yamamichi, Gaku
	Ishizuya, Yu
	Yamamoto, Yoshiyuki
	Hatano, Koji
	Kawashima, Atsunari
	Takada, Shingo
	Inoue, Hitoshi
	Nishimura, Kensaku
	Miyake, Osamu
	Fujita, Kazutoshi
	Nakayama, Masashi
	Nishimura, Kazuo
	Nonomura, Norio
citation_publisher	Springer
citation_language	英語
citation_date	2024-09-02
citation_journal_title	International Journal of Clinical Oncology
citation_volume	29
citation_issue	12
citation_firstpage	1916
citation_lastpage	1924
citation_doi	https://doi.org/10.1007/s10147-024-02612-1
citation_public_url	https://hdl.handle.net/11094/98275

Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan

閲覧可能ファイル

論文情報

論文詳細を表示